SAN JOSE, Calif., May 12 -- Laserscope will co-submit a Pre-Market Approval application to the US Food and Drug Administration for its Photodynamic Therapy (PDT) Laser Systems, in conjunction with Scotia Pharmaceuticals Ltd., UK's New Drug Application for Foscan. The submissions, expected to take place in September 1999, will be for the PDT treatment of head and neck cancer. Foscan has been assigned ``fast-track'' status by the FDA for the palliation of head and neck cancer. If granted, approval could come as early as six months after submission.